Humalog^® KwikPen™: an insulin-injecting pen designed for ease of use

References

• Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA, USA (2008).
   Google Scholar
• National Institute of Diabetes and Digestive and Kidney Diseases. National diabetes statistics, 2007 fact sheet. US Department of Health and Human Services, National Institutes of Health Bethesda, MD, USA (2008).
   Google Scholar
• American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care31(3), 596–615 (2008).
   PubMed Web of Science ®Google Scholar
• Marcus A. Diabetes care – insulin delivery in a changing world. Medscape J. Med.10(5), 120 (2008).
   PubMedGoogle Scholar
• Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care27(5), 1218–1224 (2004).
   PubMed Web of Science ®Google Scholar
• Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA291(3), 335–342 (2004).
   PubMed Web of Science ®Google Scholar
• Brown JB, Nichols GA, Perry A. The burden of treatment failure in Type 2 diabetes. Diabetes Care27(7), 1535–1540 (2004).
   PubMed Web of Science ®Google Scholar
• Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int. J. Obes. Relat. Metab. Disord.26(Suppl. 3), S18–S24 (2002).
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Lauritzen T et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care28(11), 2673–2679 (2005).
   PubMed Web of Science ®Google Scholar
• Stewart KM, Wilson MF, Rider JM. Insulin delivery devices. J. Pharm. Pract.17, 20–28 (2004).
   Google Scholar
• Bohannon NJ. Insulin delivery using pen devices. Simple-to-use tools may help young and old alike. Postgrad. Med.106(5), 57–58, 61–64, 68 (1999).
   PubMed Web of Science ®Google Scholar
• Molife C, Lee LJ, Shi L, Sawhney M, Lenox SM. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol. Ther.11(8), 529–538 (2009).
   PubMed Web of Science ®Google Scholar
• de Luis DA, Aller R, Cuellar L et al. Effect on quality of life with a new insulin injection device in elderly patients with diabetes mellitus Type 2. J. Diabetes Complicat.18(4), 216–219 (2004).
   PubMed Web of Science ®Google Scholar
• Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with Type 1 diabetes. Diabetes Care22(1), 137–140 (1999).
   PubMed Web of Science ®Google Scholar
• Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with Type 2 diabetes mellitus. Pharmacotherapy27(7), 948–962 (2007).
   PubMed Web of Science ®Google Scholar
• Davis EM, Christensen CM, Nystrom KK, Foral PA, Destache C. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization. Am. J. Health. Syst. Pharm.65(14), 1347–1357 (2008).
   PubMed Web of Science ®Google Scholar
• Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with Type 2 diabetes: a retrospective database analysis. Clin. Ther.29, 1294–1305 (2007).
   Web of Science ®Google Scholar
• Magnotti MA, Rayfield EJ. An update on insulin injection devices. Insulin. Am. J. Health Syst. Pharm.2, 173–181 (2007).
   Google Scholar
• Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care27(10), 2495–2497 (2004).
   PubMed Web of Science ®Google Scholar
• Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin. Ther.26(9), 1498–1505 (2004).
   PubMed Web of Science ®Google Scholar
• Korytkowski M, Bell D, Jacobsen C, Suwannasari R. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with Type 1 or 2 diabetes mellitus. Clin. Ther.25(11), 2836–2848 (2003).
   PubMed Web of Science ®Google Scholar
• Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin. Ther.20(3), 486–496 (1998).
   PubMed Web of Science ®Google Scholar
• Kadiri A, Chraibi A, Marouan F et al. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res. Clin. Pract.41(1), 15–23 (1998).
   PubMed Web of Science ®Google Scholar
• Stockl K, Ory C, Vanderplas A et al. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr. Med. Res. Opin.23(1), 133–146 (2007).
   PubMed Web of Science ®Google Scholar
• Gilmer TP, O’Connor PJ, Rush WA et al. Predictors of health care costs in adults with diabetes. Diabetes Care28(1), 59–64 (2005).
   PubMed Web of Science ®Google Scholar
• Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with Type 2 diabetes. J. Manag. Care Pharm.11(7), 559–564 (2005).
   PubMedGoogle Scholar
• Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with Type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin. Ther.28(10), 1712–1725 (2006).
   PubMed Web of Science ®Google Scholar
• Ignaut DA, Opincar MR, Clark PE, Palaisa MK, Lenox SM. Engineering study comparing injection force and dose accuracy between two prefilled insulin injection pens. Curr. Med. Res. Opin.25(12), 2829–2833 (2009).
   PubMed Web of Science ®Google Scholar
• Ignaut DA, Schwartz SL, Sarwat S, Murphy HL. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen. Diabetes Educ.35(5), 789–798 (2009).
   PubMed Web of Science ®Google Scholar
• Clark PE, Valentine V, Bodie JN, Sarwat S. Ease of use and patient preference injection simulation study comparing two prefilled insulin pens. Curr. Med. Res. Opin.26(7), 1745–1753 (2010).
   PubMed Web of Science ®Google Scholar
• Ignaut DA, Venekamp WJ. HumaPen Memoir: a novel insulin-injecting pen with a dose-memory feature. Expert. Rev. Med. Devices4(6), 793–802 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Muchmore D, Swanson D, Schmitke J. AIR inhaled insulin system: a novel insulin-delivery system for patients with diabetes. Expert Rev. Med. Devices4(5), 683–692 (2007).
   PubMed Web of Science ®Google Scholar